Clinical Trial Update: A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) [Phase 3]

View source ↗

Summary

Phase 3 trial in synovial sarcoma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma
• Soft Tissue Sarcoma
• Synovial Sarcoma

Snippet

Sponsor: Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Synovial Sarcoma, Cancer | Phase 3 | Status: TERMINATED | Results posted: 2020-04-16